Trials / Completed
CompletedNCT00038584
A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer
A Phase IB Study of Oral Administration of SCH 66336 Preoperatively in Patients With Head and Neck Squamous Cell Cancer Scheduled for Definitive Therapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
SCH66336 is a drug that has been designed to block the growth of tumor cells and encourage tumor cell death. This is a randomized study where patients will receive study drug or no drug. Participants in this study are scheduled to have surgery to remove head and neck cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SCH66336 |
Timeline
- Start date
- 1999-06-01
- Primary completion
- 2004-11-01
- Completion
- 2004-11-01
- First posted
- 2002-06-03
- Last updated
- 2018-10-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00038584. Inclusion in this directory is not an endorsement.